Skip to main content
. Author manuscript; available in PMC: 2018 Aug 15.
Published in final edited form as: Clin Cancer Res. 2017 Apr 26;23(16):4680–4692. doi: 10.1158/1078-0432.CCR-16-3029

Figure 1.

Figure 1

A, Example images from a representative patient biopsy (CBRC013) used for automated image segmentation. Melanoma cells are marked by staining for S100 (green); all cells are marked by DAPI (blue). B, Effects of single agents (top) and all drug combinations (bottom) are plotted as percent DMSO control, comparing results for CBRC007 when only the S100+/melanoma population are scored (x-axes) versus all DAPI+ cells (y-axes). C, Comparison between technical replicates of biopsy CBRC056 single agent screening on melanoma cell population viability. D, Comparison between biological replicates of screening CBRC029 on melanoma cell population viability. E, Effect of BRAF inhibitor PLX4720 on melanoma cell viability in patient biopsies, comparing BRAF wild-type to BRAF mutant sample results.